journal cover

Regional practice norms for the care of childhood cancer survivors at risk for cardiomyopathy: A Delphi study

Pediatric Blood & Cancer

Invalid date

Lisa B KenneyAnju Nohria

Get paper from

Abstract

Treatment-associated cardiomyopathy is a leading cause of morbidity and mortality for childhood cancer survivors (CCS). As evidence is not available to guide the management of CCS at risk for cardiomyopathy, we aim to describe the collective opinion of regional experts for the care of t...read more

Mentioned in this Paper

Adrenergic beta-Antagonists
Anthracycline Antibiotics
Cardiology Discipline
Delphi Technique
Pharmaceutical Preparations
Echocardiography
Enzyme Inhibitors
Patient Care
Physicians
Primary Health Care
3
5
Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.

Similar Papers Found In These Feeds

HFrEF

Heart failure with reduced ejection fraction (HF-rEF) is responsible for high costs and increased rates of hospital admissions along with high mortality and morbidity risks. Only treatment for HF-rEF has been shown to be efficacious compared to HF-pEF which currently has no useful treatment options. Here is the latest research on HF-rEF.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Heart Rhythm & Arrythmias

Heart arrhythmias, also known as irregular heartbeat or cardiac dysrhythmia, are a group of conditions where the heartbeat is irregular (dysrhythmia), too slow (bradycardia), or too fast (tachycardia). Discover the latest research on heart rhythm and arrythmias here.

HFpEF

HF-pEF is associated with left ventricular diastolic dysfunction and concentric left ventricular hypertrophy and has significant mortality and morbidity. The heterogeneity of the disease has resulted in the failure of any drugs for the treatment of HF-pEF. Here are the latest discoveries pertaining to this disease.

© 2019 Meta ULC. All rights reserved

Regional practice norms for the care of childhood cancer survivors at risk for cardiomyopathy: A Delphi study

Pediatric Blood & Cancer

Invalid date

Lisa B KenneyAnju Nohria

PMID: 31148382

DOI: 10.1002/pbc.27868

Abstract

Treatment-associated cardiomyopathy is a leading cause of morbidity and mortality for childhood cancer survivors (CCS). As evidence is not available to guide the management of CCS at risk for cardiomyopathy, we aim to describe the collective opinion of regional experts for the care of t...read more

Mentioned in this Paper

Adrenergic beta-Antagonists
Anthracycline Antibiotics
Cardiology Discipline
Delphi Technique
Pharmaceutical Preparations
3
5

Related Papers

Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.

Get paper from

/papers/regional-practice-norms-for-the-care-of-childhood/31148382